3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Uveal Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Colorectal Neoplasms
1
Carcinoma
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
4
Nivolumab
3
Specimen Handling
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
utomilumab
1
tislelizumab
1
spartalizumab
1
ruxolitinib
1
pentetreotide
1
niraparib
1
montanide ISA 51
1
fludarabine phosphate
1
entinostat
1
avelumab
1
Valacyclovir
1
Toll-Like Receptor 1
1
Spinal Puncture
1
Rose Bengal
1
Radiosurgery
1
LY2940680
1
Interleukin-2
1
Interleukin-13
1
Injections
1
Immunologic Techniques
1
Fluorodeoxyglucose F18
1
Cryosurgery
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Toll-Like Receptor 1
×
Thoracic
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled